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ment of patients with MPC as it delivers a survival advantage at a moderate price 
increase.
PCN194
ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF 
UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS 
AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN: COST-UTILITY 
ANALYSIS
Sanz-Granda Á1, Hidalgo-Figueruela F1, Granell M2
1Weber Economía y Salud, Majadahonda (Madrid), Spain, 2Bayer HealthCare, Sant Joan Despí ( 
Barcelona ), Spain
Objectives: To estimate the threshold price (TP) of regorafenib in Spain to be an 
efficient option in the treatment of unresectable and/or metastatic gastrointesti-
nal stromal tumors (GIST) that have progressed on imatinib and sunitinib, com-
pared with the best supportive care (BSC). MethOds: The TP is the maximum 
price at which regorafenib offers an efficient incremental cost-utility ratio (ICUR) 
in Spain (≤ 30,000 € /QALY). A probabilistic cost-utility Markov model of GIST treat-
ment was developed initially in Excel to estimate costs and benefits of regorafenib 
compared with the BSC, from a National Health System perspective, in a lifetime 
horizon. Efficacy (overall survival and progression-free survival) and utilities were 
extracted from the GRID study, and cost values (drugs, visits, monitoring, adverse 
events, and end-of-life costs), from Spanish databases and published data. Then, 
the TP was estimated by using the Solver Add-in and a cost utility analysis was 
performed. Results: The initial model estimated a total cost of 33,256 € (95CI: 
27,909-38,324), and utility of 1.718 QALY (95CI: 1,506-1,757) with regorafenib; the 
estimated values of BSC were 6,546 € (95CI: 5,637-7,026) and 1.073 QALY (95CI: 0.902-
1.112), respectively.The TP of regorafenib was estimated in 2.234 € , and the total 
cost was 25,901 € (95CI: 21,912-29,409), showing a difference compared to BSC of 
19,356 € (95CI: 16,431-21,376); the ICUR was 30,000 € /QALY (95CI: 25,556-35,795). 
The probability of cost-effectiveness with regorafenib was 51.8%, for a willingness 
to pay of 30,000 € /QALY. cOnclusiOns: Below an ex-factory price of 2.234€ , the 
treatment with regorafenib in unresectable and/or metastatic GIST whose disease 
has progressed on imatinib and sunitinib represents a cost effectiveness assigna-
tion of resources.
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THE COMPARATIvE PHARMACOECONOMIC ANALYSIS OF USING PLERIxAFOR 
FOR STEM CELL MOBILIzATION FOR AUTOLOGOUS PERIPHERAL STEM CELL 
TRANSPLANTATION FOR NON-HODGkIN’S LYMPHOMA PATIENTS
Krysanova V1, Krysanov I2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Postgraduate Medical 
Institute, Moscow National University of Food Production, Moscow, Russia
Objectives: Autologous peripheral stem cell transplantation (ASCT) with high-dose 
chemotherapy is a preferred treatment for non-Hodgkin’s lymphoma (NHL) patients. 
Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to 
G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The 
main aim of this study was to perform comparative pharmacoeconomic analysis of 
using G+P versus G-CSF as a method for SCM. MethOds: Analysis of the published 
clinical trials was conducted to evaluate comparative efficacy and safety of the 
studied therapy options. Taking into account the hypothesis of superior effective-
ness of combination G+P for SCM for pharmacoeconomic analysis was chosen 
“cost-utility” analysis. For this study was adopted a Markov model simulated the 
care process of NHL patients undergoing ASCT using data from the Washington 
University site of the plerixafor Phase III study (Kymes SM. et al, 2012). Direct medical 
costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ 
cell processing and cryopreservation. Mobilization and remobilization costs were 
defined to be the costs of medical procedures, resource utilization, and medica-
tions. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitiv-
ity analysis was made. Results: According to published trials the combination 
G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. 
Additionally, G+P mobilization resulted in more predictable days of collection, no 
weekend aphaeresis procedures, and no unscheduled hospital admissions. The 
expected lifetime cost of providing care for NHL patients using G+P was 601 294 
rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted 
life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitiv-
ity analysis showed that the results are more sensitive to the variations of key model 
parameter, such as price of plerixafor. cOnclusiOns: Using G+P for SCM in ASCT of 
patients with NHL was more effective and economically justified treatment option.
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EFFICIENCY OF ExPENSES OF GEFITINIBUM IN PATIENTS WITH NON-SMALL 
CELL LUNG CANCER AS A SECOND LINE THERAPY
Rudakova AV1, Meshkov DO2, Khabriev RU2, Bezmelnitsyna LY2
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Objectives: Therapy of non-small cell lung cancer is a very complex clinical prob-
lem. Revealing of an optimum version of therapy requires not only the analysis 
of data by clinical efficiency, but also assessments of efficiency of expenses for 
applied medical products. Objective of research was an assessment the efficiency 
of expenses of Gefitinibum in patients with non-small cell lung cancer as a second 
line therapy. MethOds: Modelling was made on the basis of results of clinical 
researches INTEREST. We considered only direct medical costs. Expenses for cor-
rection of the side effects cased hospitalization were counted on tariffs Compulsory 
Medical Service in St. Petersburg, 2013. Costs of compared medicines (Docetaxelum, 
Pemetrexed) were received from results of auctions for 01.08.2012-01.06.2013 (a 
database “Cursor”). Results: Data of the research had shown that in case of an 
inefficiency of chemotherapy of the first line therapy, Gefitinibum increased life 
expectancy in view of it’s quality on 0,013 QALY and provide savings the 276 USD for 
1 patient in comparison with original Docetaxelum. Costs for 1 month without pro-
Paquete A1, Miguel LS1, Pereira C2, Pinto CG3
1CISEP, Lisboa, Portugal, 2Roche Farmacêutica Bioquímica, Lda., Amadora, Portugal, 3University of 
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Objectives: To assess the incremental cost‐effectiveness ratio (ICER) of obinutu-
zumab in association with chlorambucil (GClb) for CLL previously untreated patients 
unsuitable for full-dose fludarabine based therapy, in the Portuguese National 
Health Service (NHS) perspective. Comparators are rituximab in association with 
chlorambucil (RClb) and chlorambucil alone (Clb). MethOds: A Markov model 
developed by Roche was used to predict disease progression and mortality, assum-
ing weekly cycles and a 25 years’ time horizon. Pre‐progression clinical data was 
based on CLL11 clinical trial (Goede et al.; 2015), and post‐progression data based 
on Eichhorst et al. (2009). Utility values were obtained on Kosmas et al. (2014). Only 
direct medical costs were included, being resource consumption estimated through 
a seven Portuguese experts panel and unit costs taken from official sources. A 5% 
discount rate was applied to both costs and consequences. Results: In comparison 
to RClb, GClb use allows an increase of 0.69 life years (LY) and of 0.66 quality adjusted 
life years (QALY) that are associated to an additional cost of 12,472€ . When compared 
to Clb, the use of GClb increases clinical gains by 1.07 LY and 0.99 QALYs at an addi-
tional cost of 24,104€ . Consequently, GClb costs 18,112€ per LY and 18,948€ per QALY 
in comparison to RClb and 22,447€ per LY and 24,352€ per QALY in comparison to 
Clb. Sensitivity analysis shows that results are mainly sensitive to the extrapolation 
methods of pre‐progression survival and to utility values. cOnclusiOns: The use 
of obinutuzumab in association with chlorambucil for CLL previously untreated 
patients that are unsuitable for full-dose fludarabine based therapy implies added 
costs per LY and per QALY that are generally accepted in Portugal. The cost‐effec-
tiveness ratios of obinutuzumab in association with chlorambucil (GClb) are below 
25,000€ when compared both to rituximab in association with chlorambucil (RClb) 
and to chlorambucil alone (Clb).
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COST-EFFECTIvENESS OF CETUxIMAB IN FIRST-LINE TREATMENT OF 
PATIENTS WITH METASTATIC COLORECTAL CANCER IN BELGIUM AND THE 
NETHERLANDS
Krol M1, Ovcinnikova O2, von Hohnhorst P3, Jarrett J2
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Objectives: This study aimed to assess the cost-effectiveness of first-line treat-
ment of patients with cetuximab in combination with either FOLFOX or FOLFIRI 
with wild type rat sarcoma viral oncogene (RASwt) metastatic colorectal cancer 
in Belgium (B) and the Netherlands (NL) compared with treatment with FOLFOX 
or FOLFIRI. MethOds: A Markov model was developed to estimate the incremen-
tal cost-utility ratios (ICURs) of the following first-line treatment comparisons: 
cetuximab + FOLFIRI vs. FOLFIRI and cetuximab + FOLFOX vs. FOLFOX. The model 
was populated with trial data where possible. Only head-to-head trials were con-
sidered including cetuximab and RASwt data. Survival was estimated based on a 
disease modelling approach. Two versions of the model were created; one for NL 
and one for B. Country specific costs were included and second- and third-line 
treatments differed between NL and B. In line with the country’s health economic 
guidelines, analyses were conducted from a societal perspective (NL) or a health care 
perspective (B). Costs were discounted with 4% (NL) or 3% (B) and effects with 1.5%. 
The models adopted a 20 year time-horizon. A probabilistic sensitivity analysis 
was conducted to account for uncertainty. Results: The ICURs for NL and B were 
€ 86,180 and € 55,430 for cetuximab + FOLFIRI vs. FOLFIRI and € 83,151 and € 42,453 
for cetuximab + FOLFOX vs. FOLFOX. Uncertainty around the ICURs was relatively 
small in the FOLFIRI arms and considerable in the FOLFOX arms. cOnclusiOns: 
NL and B have no official ICUR thresholds, but unofficial upper limits are assumed 
to be around € 80,000 in NL and € 45,000 in B. ICURs were close to these limits. ICURs 
differed strongly between NL and B. This was mainly caused by lower drug costs in B.
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GEMCITABINE IN METASTATIC PANCREATIC CANCER IN SLOvAk REPUBLIC
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Objectives: Nab-paclitaxel is a solvent-free paclitaxel formulation approved for 
first-line treatment of patients with metastatic pancreatic cancer (MPC) in combi-
nation with gemcitabine. Treatment with nab-paclitaxel and gemcitabine has been 
shown to be clinically effective in an area of high unmet need. Patients treated 
with nab-paclitaxel and gemcitabine had an increase in median survival of 3.3 
months compared to those treated with gemcitabine alone in patient subgroup 
with Karnofsky Performance Score 70-80. MethOds: A Markov cohort model was 
constructed for patients with MPC to examine the costs and outcomes of nab-
paclitaxel and gemcitabine versus gemcitabine. Health outcomes were expressed 
in terms of life-years (LYs) and quality-adjusted life-years (QALYs) gained. Patient’s 
disease progression over time was modeled using data from the MPACT study. An 
area under the curve methodology was used to characterize patients’ disease status 
at different points in time. Parametric curves were fitted to the overall survival data, 
progression-free survival data and time on treatment data. Health Related Quality 
of Life data for each health state was sourced systematically from the literature. 
Resource unit costs and use were derived from local cross-sectional survey. The 
analysis was performed from payer’s perspective in Slovak settings. Results: The 
base case result was an incremental cost-effectiveness ratio (ICER) of € 27,769 per 
QALY gained for paclitaxel albumin plus gemcitabine versus gemcitabine, based on 
an incremental cost of € 5,943, incremental survival of 3.3 months and incremental 
QALYs of 0.214. The key driver of the incremental costs was the additional drug 
acquisition cost of adding nab-paclitaxel to gemcitabine. cOnclusiOns: € 28 820 
per QALY is defined as the upper limit for conditional reimbursement in Slovakia. 
Nab-paclitaxel and gemcitabine is the cost-effective option for the first-line treat-
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studies. Results: We estimated the indirect cost of cancer due to disability in EU 
at the amount of 4223.2 million EUR. However partial disability account for approx. 
20-25% of this sum and reduces potential savings to the amount of 844.6–1055.8 
million EUR. Further correction, taking into account the efficacy of rehabilitation 
programs (up to 85%), reduces this savings to 717.9–897.4 million EUR. Considering 
the loss of productivity due to sickness absence and presenteeism measured in 
cancer survivors’ population (19.1% and 37.3% respectively) potential savings for EU 
economy due to return to work of cancer survivors with a disability are calculated 
at the amount of 364.2-455.2 million EUR. cOnclusiOns: Indirect cost of cancer 
related disability can be reduced, but probably only to a small extent.
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PREDICTING FUTURE NEED OF RESOURCES FOR ADENOMA SURvEILLANCE 
FROM A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM 
THROUGH DISCRETE EvENT SIMULATION
Comas M1, Andreu M2, Guerrero-Ludueña RE2, Bessa X2, Balagué F3, Castells X1
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Objectives: European guidelines recommend colorectal cancer screening of 
average-risk population. Besides cancer, adenomas deserving surveillance through 
colonoscopy, are found. Our objective was to estimate the resources needed to 
undergo the recommended surveillance of adenomas found under a population-
based colorectal cancer screening program. MethOds: A previous discrete-event 
simulation model representing a colorectal cancer screening program for a target 
population of women and men aged 50-69 was used. The underlying conceptual 
model was based on the European Guidelines for both the screening process and 
follow-up after adenoma removal. Resources needed according to findings of the 
colonoscopy at screening were the following: genetic tests for polyposis; high-
complexity colonoscopies for high-risk adenomas and polyposis, non-complex 
colonoscopies for intermediate-risk adenomas; visits with gastroenterologists for 
high-risk adenomas and polyposis and with general practitioners for intermediate-
risk adenomas. Parameters were estimated from the Colorectal Cancer Screening 
Program of Barcelona and follow-up colonoscopy results from the literature. A 
20-year horizon starting in 2015 was simulated. The model included population’s 
ageing. Results were rescaled to the population of the whole territory (1.7 million 
target population). Results: The predicted number of colonoscopies at screen-
ing was 19,275, 18,829 and 20,988 for years 2015, 2024 and 2034, respectively. The 
predicted numbers of non-complex and high-complexity colonoscopies were 9,887 
and 7,760 in 2024 and 14,362 and 9,099 in 2034, respectively. The expected num-
ber of gastroenterologist and general practitioner visits were 9,137 and 15,154 in 
2024 and 10,494 and 19,989 in 2034, respectively. The number of genetic tests was 
545 and 659 for years 2024 and 2034, respectively. cOnclusiOns: Implementing 
a population-based colorectal cancer screening program represents an increased 
demand of resources for surveillance of intermediate and high-risk adenomas found 
under the program. Results of the simulation model will allow distributing the 
resources geographically and predicting future need when the screening program 
is extended to all the territory.
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EvALUATION OF RESOURCE UTILIzATON FOR CHEMOTHERAPY 
INDUCED NAUSEA AND vOMITING (CINv) IN PATIENTS TREATED WITH 
ANTHRACYCLINE+CYCLOPHOSPHAMIDE (AC) FOR SOLID CANCERS WITH AND 
WITHOUT Nk-1 BASED REGIMENS
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Objectives: This study assesses frequency of CINV events and resource utiliza-
tion in patients treated with AC for solid cancers MethOds: The study evaluated 
a randomly selected cohort of patients from Inovalon’s MORE2Research Edition 
claims database that includes longitudinal data from US health plans. Patients 
who received AC regimens on first day of each cycle in first line of therapy during 
last six months of 2013 were included. Total CINV events and CINV related and 
total hospital/ER visits were captured for cycles of interest in first line and were 
analyzed using chi-square to determine statistical differences between patients 
on NK-1 regimens and non-NK-1 regimens. Results: The study cohort consisted 
of 353 patients, 97% female, 60% with Commercial insurance, and 95% with breast 
cancer, with mean age of 53.1 and Charlson comorbidity score of 6.0. NK-1 based 
CINV regimens were utilized in 73% of the patients in the first chemotherapy cycle. 
Rescue anti-emetics were used by 53% of patients on NK-1 regimens versus 60% 
of patients on non NK-1 regimens. Frequency of CINV events was 41% for NK-1 
versus 45% for the non NK-1 group. Frequency of CINV related ER visits was 5% 
in the NK-1 group versus 12% in the non NK-1 group, p= 0.03. CINV related hospi-
talizations were 3% in the NK-1 group versus 4% in the non-NK-1 group. Total ER 
visits were lower in the NK-1 group compared to the non NK-1 group, 12% versus 
19%; total hospitalizations were also lower in the NK-1 group compared to the non 
NK-1 group, 8% versus 13%. cOnclusiOns: For patients on highly emetogenic 
AC based chemotherapy regimens, NK-1 treatments result in decreased rates of 
CINV events and resource utilization, with CINV related ER visits statistically lower. 
Further studies are warranted to determine if results are generalizable to other 
cancer regimens and diagnoses.
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RESOURCE UTILIzATION IN PATIENTS WITH ADvANCED MELANOMA IN 
FRANCE
Flinois A1, Sassolas B2, Leccia M3, Levy-Bachelot L4, Godard C5, Montin R4, Bedane C6, 
Pacou M7
gressing were 2 813 and 2 703 USD for Docetaxelum and Gefitinibum, respectively. 
Costs of 1 treatment course (21 days) of Pemetrexed were in 1,9 times higher than 
Gefitinibum. Therapy with Gefitinibum increase of life expectancy on 6 months and 
on 0,226 QALY in comparison with Pemetrexed. Costs of 1 month without progres-
sion for Gefitinib were in average 1,8 times less (2 699 and 5 016 USD for Gefitinib 
and Pemetrexed, respectively). Therapy with Gifinitib allows to decrease the direct 
medical costs on 19%. cOnclusiOns: Therapy with Gifinitib as the second line 
therapy in patients with non-small cell lung cancer is effective from clinical and 
economical point of view.
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THE IMPACT OF PHARMACEUTICAL INNOvATION ON PREMATURE CANCER 
MORTALITY IN PORTUGAL
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Objectives: Reducing premature mortality is a crucial public health objective. A 
widely used measure of premature mortality is years of potential life lost before 
a given age (e.g. age 80). The aim of this study was to analyze the effect that phar-
maceutical innovation had on premature cancer mortality in Portugal during the 
period 2002-2010. MethOds: The analysis was performed by using a difference-
in-differences research design based on longitudinal disease-level data, in order to 
investigate whether the diseases that had a larger increase in the number of new 
available drugs (i.e. more pharmaceutical innovation) had larger declines in years of 
potential life lost before age 80 in Portugal. Herein, we present the results specific for 
cancer disease. This methodology controls for the effects of macroeconomic trends 
and overall changes in the healthcare system. Official databases were used, such as 
the Eurostat for the premature mortality data. Results: Drugs registered during 
the period 1994-2002 reduced the number of years of potential life lost to cancer 
before age 80 in 2010 by 26,645. The estimates indicate that if no drugs had been 
registered during 1994-2002, premature mortality from cancer would have increased 
by about 9%. The 2010 expenditure on cancer drugs registered during 1994-2002 
in Portugal was € 148,670,718. Thus, the estimated cost per life-year before age 80 
gained from previous pharmaceutical innovation was € 5,580 (reduction in hospital 
costs due to the impact of pharmaceutical innovation on cancer morbidity were not 
accounted). cOnclusiOns: These findings indicate that pharmaceutical innova-
tion contributed with a significant reduction in the premature mortality caused by 
cancer in Portugal. Moreover, the estimated cost per life-year is well below even the 
lowest estimates of the value of a life-year saved.
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CANCER AND PREMATURE MORTALITY IN IRELAND: AN EMPLOYER’S 
PERSPECTIvE FOLLOWING THE FRICTION COST APPROACH
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Objectives: Cancer is the second leading cause of death in Ireland accounting for 
approximately 30% of all deaths. Of these, almost a third arise in those of working 
age. As well as the public health burden, cancer also imposes economic costs on 
society in general and employers in particular. This study measured the productivity 
costs associated with cancer-related premature mortality from an employer’s per-
spective in Ireland. MethOds: Data was abstracted on the average annual number 
of cancer deaths between the ages of 15 and 64 in Ireland during 2005-2009 by 5-year 
age group and sex from the World Health Organization Cancer Mortality Database. 
The friction cost approach was used to value all premature cancer deaths (and those 
for the ten most common cancer sites in males and females), over a defined friction 
period (base-case = 79 days), by gross gender- and age-specific wages, adjusted for 
labour market characteristics. In sensitivity analyses estimates were adjusted for 
‘multiplier effects’ associated with modern work practices and for changing labour 
market conditions. Results: The all-cancer premature mortality cost was € 14.3 mil-
lion in 2009. Costs were more than two-fold higher for males than females. Base-case 
estimates were sensitive to changes in labour markets conditions and decreased by 
42% following adjustment for increased unemployment levels (from 4.6% to 12.7%). 
Productivity costs were higher in settings with modern team-based working prac-
tices rising by almost 30% in the case of females (17% for males). cOnclusiOns: 
Employers are becoming increasingly aware of the adverse economic effects of illness. 
Our results reveal the magnitude of productivity costs associated with cancer-related 
premature mortality from an employer’s perspective in Ireland. These results provide 
a sense of the types and magnitude of costs that are explicitly excluded from eco-
nomic evaluations that fail to encompass a broader social perspective.
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POTENTIAL SAvINGS TO EU ECONOMY DUE TO RETURNING TO WORk OF 
CANCER SURvIvORS WITH A DISABILITY
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Objectives: The number of cancer survivors is growing due to progression in diag-
nosis and treatment. Approximately half of cancer survivors are at working age, 
however many of them do not return to work. One of the reasons is a disability of 
cancer survivors. Although cancer related disability is usually more severe compared 
to disability due to other diseases, real-life data showed up to 85% of disabled cancer 
survivors may return to work after comprehensive rehabilitation programs. The aim 
of this study was to estimate potential savings to EU economy due to return to work 
of disabled cancer survivors. MethOds: Data on indirect cost of a cancer related 
disability were calculated based on Luengo-Fernandez at al. study and our own esti-
mation of a contribution of disability to indirect cost related to morbidity. Disability 
structure i.e. percentage of a partially disabled cancer survivors, was adopted from 
Polish Social Insurance Institution data (we assumed that population with complete 
disability or inability for independent existence can’t return to work). Presenteeism 
and absenteeism in cancer survivors were adopted from our previously published 
